Fig. 4

Synergistic effect of chidamide combined with enzalutamide in vivo and ex vivo. A-D Representative tumor images A, tumor growth curves B, endpoint tumor weight C bar plots and endpoint mouse weight bar plots (D) for different treatment groups. E Representative brightfield images of patient-derived organoids (PDOs) on day 5 after drug treatment. PDO models of LAR and non-LAR subtypes were treated with DMSO (control), 1 μM chidamide, 1 μM enzalutamide or the combination therapy for 5 days. Scale bar, 200 μm.Viability was calculated by each group compared with group blank (PDOs without any additional treatment). Abbreviations: LAR, luminal androgen receptor. The data are presented as the mean ± SEM and were compared using Student’s t test (B-D) or Kruskal-Wallis test (E) ****indicates P < 0.0001; ***indicates P < 0.001; **indicates P < 0.01; *indicates P < 0.05; ns indicates no significance